Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Reach of needle and syringe programmes needs to extend

News team

Needle and syringe programmes targeted at people who inject image- and performance-enhancing drugs are needed, according to the latest “Shooting up” report from Public Health England, published last week (8 November 2013).

The report — which describes the extent of infections among people who inject drugs in the UK to the end of 2012 — says that people who inject image- and performance-enhancing drugs, such as anabolic steroids and tanning drug melanotan, are at greater risk of HIV, hepatitis B and hepatitis C infection than previously thought. It adds that, in England and Wales, the level of HIV infection among this group is similar to that among people who inject psychoactive drugs, such as heroin and crack-cocaine.

The report also highlights that infections remain common among people who inject psychoactive drugs. Half of this group have been infected with hepatitis C; around one in 100 has HIV; and almost one-third report having a recent injection site infection. However, hepatitis B infection among this group has declined, which the report says is probably due to an increase in uptake of hepatitis B vaccination. The report also describes a recent increase in the injection of amphetamines and amphetamine-type drugs, such as mephedrone, explaining that there is evidence that injecting these drugs is associated with higher levels of infection risk than injecting other psychoactive drugs.

Separately, Public Health England last week (6 November 2013) published its annual report on drug treatment activity in England for 2012–13. The report says that adult drug treatment programmes in England continued to perform well, helping over 29,000 people to recover from addiction. The total number of people in treatment during 2012–13 was 193,575, down from 197,110 in 2011–12 and from a peak of 210,815 in 2008–09.

However, despite reporting an overall decline in drug use and a move away from the most problematic substances, the Government body warns that services “need to adapt and respond effectively to changing patterns in drug use and the needs of the wider population, such as those who get into problems with new psychoactive substances and prescription or over-the-counter medicines”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11130105

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £81.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Hepatitis C virus (LuisAzevedo/iStockPhoto)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.